Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial

医学 美罗华 安慰剂 内科学 临床终点 风湿病 痹症科 临床试验 物理疗法 外科 淋巴瘤 替代医学 病理
作者
Satoshi Ebata,Ayumi Yoshizaki,Koji Oba,Kosuke Kashiwabara,Keiko Ueda,Yukari Uemura,Takeyuki Watadani,Takemichi Fukasawa,Shunsuke Miura,Asako Yoshizaki‐Ogawa,Yoshihide Asano,Naoko Okiyama,Masanari Kodera,Minoru Hasegawa,Shinichi Sato
出处
期刊:The Lancet Rheumatology [Elsevier BV]
卷期号:3 (7): e489-e497 被引量:302
标识
DOI:10.1016/s2665-9913(21)00107-7
摘要

Background Systemic sclerosis is a connective tissue disease characterised by multiorgan fibrosis with an autoimmune background and poor prognosis. Although a few drugs have shown some efficacy in treating the disease, there remains a great unmet medical need. We aimed to investigate the efficacy and safety of rituximab in patients with systemic sclerosis. Methods We did a double-blind, investigator-initiated, randomised, placebo-controlled trial at four hospitals in Japan. Patients aged 20–79 years, who fulfilled the 2013 American College of Rheumatology and European League Against Rheumatism classification criteria for systemic sclerosis, with a modified Rodnan Skin Score (mRSS) of 10 or greater, and an expected survival of at least 6 months were randomly assigned (1:1) to receive intravenous rituximab (375 mg/m2) or placebo once per week for 4 weeks. Patients and investigators were masked to treatment allocation. The primary endpoint was the absolute change in mRSS 24 weeks after initiation of study treatment, measured in all patients who received at least one dose of study treatment and had one endpoint assessment. This study is registered with ClinicalTrials.gov, NCT04274257, and UMIN-CTR, UMIN000030139. Findings Between Nov 28, 2017, and Nov 6, 2018, 80 individuals were screened and 56 (70%) were enrolled and randomly assigned; 51 (91%) were women and five (9%) were men. 27 (96%) of 28 patients in the rituximab group and 22 (79%) of 28 patients in the placebo group received at least one dose of their allocated treatment and completed 24 weeks of follow-up. The absolute change in mRSS 24 weeks after initiation of study treatment was lower in the rituximab group than in the placebo group (−6·30 in the rituximab group vs 2·14 in the placebo group; difference −8·44 [95% CI −11·00 to −5·88]; p<0·0001). Adverse events were similar in both groups and occurred in 28 (100%) of 28 patients in the rituximab group and 23 (88%) of 26 patients in the placebo group. One serious adverse event leading to treatment discontinuation occurred in one patient in each group (decreased serum albumin in the rituximab group and biliary enzyme increase in the placebo group). The most common adverse event was upper respiratory infection, which occurred in 11 patients (39%) in the rituximab group and ten patients (38%) in the placebo group. There were no deaths during follow-up. Interpretation Rituximab appears to be an effective and safe treatment for systemic sclerosis. Although this study has some limitations, this is the first clinical trial to show efficacy of rituximab with skin sclerosis as the primary endpoint. Funding Japan Agency for Medical Research and Development (AMED), Zenyaku Kogyo. Translation For the Japanese translation of the abstract see Supplementary Materials section.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
华仔的应助被L劉采纳,获得10
4秒前
汪洋慧完成签到 ,获得积分10
9秒前
丘比特的应助被魁梧的钧采纳,获得10
9秒前
丽丽完成签到 ,获得积分10
12秒前
七QI完成签到 ,获得积分10
13秒前
朴实夏寒完成签到,获得积分10
13秒前
阮文名完成签到,获得积分10
14秒前
好风起完成签到 ,获得积分10
15秒前
asdfqaz完成签到,获得积分10
17秒前
周舒鱼完成签到 ,获得积分10
17秒前
18秒前
HAPPY完成签到,获得积分10
19秒前
稳重萃发布了新的文献求助10
22秒前
molihuakai的应助被魁梧的钧采纳,获得10
23秒前
Alex完成签到,获得积分10
24秒前
heart完成签到,获得积分10
25秒前
南枝焙雪完成签到 ,获得积分10
26秒前
Banana完成签到,获得积分10
27秒前
负责的紫安完成签到 ,获得积分10
28秒前
liuchuanfa34完成签到,获得积分10
31秒前
zxy的应助被科研通管家采纳,获得10
33秒前
无极微光的应助被科研通管家采纳,获得20
33秒前
zxy的应助被科研通管家采纳,获得10
33秒前
qinyaopanda的应助被科研通管家采纳,获得10
33秒前
zxy的应助被科研通管家采纳,获得10
34秒前
zxy的应助被科研通管家采纳,获得10
34秒前
群青完成签到 ,获得积分10
37秒前
二碘化钾完成签到 ,获得积分10
38秒前
Ray完成签到,获得积分10
38秒前
南枝焙雪完成签到 ,获得积分10
44秒前
科研通AI65的应助被怡然小白菜采纳,获得10
44秒前
程转完成签到 ,获得积分10
45秒前
炸鲜奶完成签到,获得积分10
50秒前
勤劳觅山完成签到,获得积分10
53秒前
zhh完成签到,获得积分10
57秒前
鸡蛋酱完成签到 ,获得积分10
59秒前
小菜鸟一碰就碎完成签到 ,获得积分10
1分钟前
科研小白009完成签到 ,获得积分10
1分钟前
原点完成签到,获得积分10
1分钟前
mochenyun完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185520
求助须知:如何正确求助?哪些是违规求助? 9574262
关于积分的说明 21834654
捐赠科研通 7783176
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558951
邀请新用户注册赠送积分活动 2481357